Sanctuary Advisors LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Sanctuary Advisors LLC trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 26.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,379 shares of the medical research company's stock after selling 6,293 shares during the period. Sanctuary Advisors LLC's holdings in Charles River Laboratories International were worth $3,402,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of CRL. Virtu Financial LLC acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $601,000. State Street Corp boosted its position in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after buying an additional 41,421 shares in the last quarter. Quest Partners LLC grew its stake in shares of Charles River Laboratories International by 135,175.0% during the second quarter. Quest Partners LLC now owns 5,411 shares of the medical research company's stock worth $1,118,000 after buying an additional 5,407 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Charles River Laboratories International by 3.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock worth $22,060,000 after buying an additional 3,714 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after acquiring an additional 3,268 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Down 0.4 %

NYSE:CRL traded down $0.74 during trading hours on Tuesday, reaching $189.33. The company had a trading volume of 572,219 shares, compared to its average volume of 616,935. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $9.68 billion, a price-to-earnings ratio of 23.70, a P/E/G ratio of 5.00 and a beta of 1.38. The business's 50-day simple moving average is $194.37 and its two-hundred day simple moving average is $202.82.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $975.99 million. During the same quarter in the prior year, the firm earned $2.72 EPS. The business's revenue was down 1.6% on a year-over-year basis. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CRL. Evercore ISI boosted their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research report on Thursday, November 7th. StockNews.com downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. Bank of America dropped their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a report on Friday. Citigroup lowered shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and reduced their target price for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, Robert W. Baird cut their price target on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating on the stock in a report on Friday, September 20th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $214.00.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the business's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company's stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).